SEC Tracker
Get the app

Disc Medicine IRON

Disc Medicine announces positive APOLLO trial results

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. Bitopertin met all primary and secondary endpoints in APOLLO Phase 3 trial
  2. Reduction in whole-blood PPIX by 41.4% vs. placebo (p<0.0001)
  3. Increase in average monthly light time without pain by 12.2 hours vs. placebo (p=0.0010)
  4. Bitopertin was generally well-tolerated with no Grade 3 TEAEs

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Disc Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  2. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025
  3. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  4. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  5. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025